STI571:: Bcr-Abl kinase inhibition as the basis of therapy for CML

被引：0
|
作者：
Mauro, MJ [1 ]
Druker, BJ [1 ]
机构：
[1] Oregon Hlth Sci Univ, Portland, OR 97201 USA
来源：
LEUKEMIA | 2001年 / 15卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O23
引用
收藏
页码：488 / 488
页数：1
相关论文
共 50 条
  • [31] Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571:: diverse mechanisms of resistance
    Mahon, FX
    Deininger, MWN
    Schultheis, B
    Chabrol, J
    Reiffers, J
    Goldman, JM
    Melo, JV
    BLOOD, 2000, 96 (03) : 1070 - 1079
  • [32] Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
    Weisberg, E
    Griffin, JD
    BLOOD, 2000, 95 (11) : 3498 - 3505
  • [33] Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation
    Hofmann, WK
    Jones, LC
    Lemp, NA
    de Vos, S
    Gschaidmeier, H
    Hoelzer, D
    Ottmann, OG
    Koeffler, HP
    BLOOD, 2002, 99 (05) : 1860 - 1862
  • [34] Minimal residual disease (MRD) analysis of BCR-ABL positive acute lymphocytic leukemia (ALL) patients during STI571 kinase inhibitor therapy.
    Scheuring, UJ
    Wassmann, B
    Pfeiffer, H
    Capdeville, R
    Petershofen, E
    Gschaidmeier, H
    Hoelzer, D
    Ottmann, OG
    BLOOD, 2000, 96 (11) : 465A - 465A
  • [35] New BCR-ABL inhibitors overcome resistance to STI-571
    Hitt, E
    LANCET ONCOLOGY, 2001, 2 (12) : 713 - 713
  • [36] STI571 reduces NER activity in BCR/ABL-expressing cells
    Sliwinski, Tomasz
    Czechowska, Agnieszka
    Szemraj, Janusz
    Morawiec, Zbigniew
    Skorski, Tomasz
    Blasiak, Janusz
    MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2008, 654 (02) : 162 - 167
  • [37] In vitro effects of PS-341 alone and in combination with STI571 in Bcr-Abl positive cell lines both sensitive and resistant to STI571.
    Gatto, SR
    Scappini, B
    Verstovsek, S
    Milella, M
    Onida, F
    Ball, G
    Kantarjian, HM
    Keating, MJ
    Cortes, JE
    Beran, M
    BLOOD, 2001, 98 (11) : 101A - 101A
  • [38] Bcr-Abl inhibition as a modality of CML therapeutics
    Buchdunger, E
    Matter, A
    Druker, BJ
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2001, 1551 (01): : M11 - M18
  • [39] Overproduction of BCR-ABL induces apoptosis in STI571-resistant BaF/BCR-ABL cell lines.
    Desplat, V
    Belloc, F
    Lagarde, V
    Melo, JV
    Reiffers, J
    Mahon, FX
    BLOOD, 2001, 98 (11) : 148A - 148A
  • [40] Results of imatinib mesylate (STI571), a bcr-abl tyrosine kinase inhibitor, in Philadelphia chromosome-positive chronic myelogenous leukemia in blastic phase (Ph plus CML BP).
    Kantarjian, HM
    Cortes, J
    O'Brien, S
    Giles, F
    Albitar, M
    Rios, MB
    Shan, J
    Faderl, S
    Garcia-Manero, G
    Issa, JP
    Thomas, D
    Capdeville, R
    Talpaz, M
    BLOOD, 2001, 98 (11) : 260B - 260B
12345